je.st
news
Tag: signs license
New York Power Authority Signs Software License Agreement
2014-03-13 17:08:00| Transmission & Distribution World
GE Energy Consulting and the New York Power Authority have agreed to a one-year license arrangement allowing NYPA to use GEs Multi-Area Production Simulation software. read more
Tags: software
york
power
agreement
GE Energy Consulting Signs Multiple Software License Agreements
2014-03-06 05:00:00| Industrial Newsroom - All News for Today
GE Energy Consulting Signs Software License Agreement with New York Power Authority<br /> <br /> SCHENECTADY, N.Y. – Building on a long-standing business relationship, GE Energy Consulting and the New York Power Authority (NYPA) have agreed to a one-year license arrangement allowing NYPA to use GE's Multi-Area Production Simulation (MAPS) software. NYPA is expanding its current modeling capabilities to perform high-fidelity nodal analysis and has chosen GE's MAPS software as the best ...This story is related to the following:Simulation Software | Data Analysis Software | Software
Tags: software
license
multiple
energy
ViXS signs RDK license
2014-02-27 12:30:40| Digital TV News
ViXS Systems (TSX:VXS) has announced that it is the first company with a shipping Ultra HD 4K HEVC 10-bit solution to sign the Reference Design Kit (RDK) agreement from RDK Management.
Tags: license
signs
signs license
vixs
Retrophin Signs U.S. License Agreement for Syntocinon Nasal Spray (Oxytocin)
2013-12-19 08:09:31| dairynetwork News Articles
Retrophin, Inc. recently announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon™ Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties. Syntocinon™ Nasal Spray was approved in the U.S. in 1960 to assist initial postpartum milk ejection, but was discontinued by Novartis in 1997 for
Tags: agreement
license
signs
spray
Retrophin Signs U.S. License Agreement For Syntocinon Nasal Spray (Oxytocin)
2013-12-19 08:09:31| drugdiscoveryonline News Articles
Retrophin, Inc. recently announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon™ Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties. Syntocinon™ Nasal Spray was approved in the U.S. in 1960 to assist initial postpartum milk ejection, but was discontinued by Novartis in 1997 for
Tags: agreement
license
signs
spray